Indexed metadata

Nurse practitioner‐delivered cognitive–behavioral treatment as a novel implementation route for irritable bowel syndrome: A proof of concept

Helen Burton Murray, Imani Weeks, Andrea Thurler, Samantha Calabrese, Mary Kate Lapinel, Elizabeth N Madva, Kyle Staller, Laurie Keefer, Braden Kuo

Source record

Source: Crossref

Published: Jan 20, 2023

DOI: 10.1111/nmo.14526

Open original source ↗

Source abstract

Abstract Background Exposure‐based cognitive–behavioral therapy (exposure‐CBT) is efficacious for irritable bowel syndrome (IBS). However, few patients receive exposure‐CBT due to a lack of behavioral health providers trained in brain–gut behavior therapies. Nurse practitioners (NPs) could fill a critical need for scalable delivery methods. In a pragmatic investigation of a 5‐session NP‐delivered exposure‐CBT for adults with Rome IV‐defined IBS, we evaluated treatment feasibility and acceptability and explored changes clinical outcomes. Methods Exposure‐CBT was delivered as part of routine care involving four sessions every other week and a 2‐month booster session. Patients could electively participate in an observational study including pre‐, mid‐, and post‐treatment surveys and a post‐treatment qualitative interview. Independently coded ratings of NP treatment protocol adherence and competence ratings were completed from audio recordings, rated on a 1 (not at all) to 5 (completely) scale. Results Twenty‐five patients consented (ages 22‐67 years; 76% female; 48% IBS‐diarrhea predominant). There was high feasibility—adherence average = 4.1, NP competence average = 4.8, 72% treatment completion, 93% satisfaction scores ≥3. Treatment satisfaction was high (rated as 4/4 “very satisfied” by n = 9 and as 3/4 “mostly satisfied” by n = 5). There were improvements in clinical outcomes across treatment with large effects for IBS‐symptom severity (−53%; Hedge's g = 1.0; 95% confidence interval [CI] = 0.5, 1.5) and IBS quality of life (+31%; Hedge's g = 0.8; 95% CI = 0.4, 1.2). Conclusions NP‐delivered exposure‐CBT for IBS was initially feasible and acceptable with promising clinical improvements. Findings will inform a future NIH Stage 1B/ORBIT Phase IIB pilot randomized control trial.

Evidence graph

No public relationships recorded yet.

Integrity note: This page is a factual metadata record created by deterministic ingestion. It is not a claim that the work moves a mathematical frontier or has been independently verified.